Business
Berkshire Hathaway stock portfolio and SOTP
Sherwood News

Warren Buffett’s Berkshire Hathaway jumps after earnings grew 71%

What exactly does the company own?

Shares in Berkshire Hathaway are up this morning as investors react to a bumper set of results — operating profit rose 71% in Q4 — while also digesting the ever-growing cash pile at the conglomerate.

Rainy day fund?

Investors who pay heed to Buffett’s moves for insights into the broader market have been nervous about Berkshire’s growing cash hoard over the years, wondering if the mountain of cash reflects a tacit fear of a market fall. So, the revelation that it had swelled to some $334 billion — the highest on record — compounded some investors’ jitters.

However, in last weekend’s annual letter, Buffett assured shareholders that “the great majority of your money remains in equities. That preference won’t change.”

Buffett is, of course, correct.

Taken at face value, cash and cash equivalents currently account for less than one-third of the company’s $1.03 trillion market cap. Another $272 billion is accounted for by its public stock portfolio, and the remainder would theoretically be the value of its actual operating businesses: companies predominantly in railroads, insurance, and energy, minus any associated debt or liabilities they have.

The sale of its biggest, highly appreciated holdings like Apple, which helped Berkshire hoard piles of cash by the end of last year, means that the company has also reached new highs in corporate taxes this year, paying a staggering $26.8 billion in 2024 alone, roughly 5% of the total taxes paid by US companies last year, per Buffett.

More Business

See all Business
Strive Pharmacy recently broke ground on a new facility in Mesa, Arizona. (Strive Pharmacy)

Before Hims’ GLP-1 pill fallout, its pharmacy partner was already drawing scrutiny from state regulators

Strive has already been probed over the timing of its GLP-1 compounding. Now, Arizona regulators are looking into complaints about ketamine misuse and improper distribution of prescription drugs.

business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.